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Medulloblastoma is the most common pediatric brain tumor. We
describe a child with tuberous sclerosis complex that developed
a Group 3, myc overexpressed, metastatic medulloblastoma (MB).
Considering the high risk of treatment-induced malignancies, a tai-
lored therapy, omitting radiation, was given. Based on the evidence
of mammalian target of rapamycin mTORC, mTOR Complex; RAS,
Rat sarcoma; RAF, rapidly accelerated fibrosarcoma (mTOR) path-
way activation in the tumor, targeted therapy was applied resulting
in complete remission of disease. Although the PI3K/AKT/mTOR sig-
naling pathway plays a role in MB, we did not find TSC1/TSC2 (TSC,
tuberous sclerosis complex) mutation in our patient. We speculate
that a different pathway resulting in mTOR activation is the basis of
both TSC and MB in this child; H&E, haematoxilin and eosin; Gd,
gadolinium. Pediatr Blood Cancer C© 2015 Wiley Periodicals, Inc.
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INTRODUCTION
Medulloblastoma (MB) is the most common malignant
central nervous system (CNS) tumor of childhood. Current
multimodal treatment of MB has led to a 5-year overall survival
of about 87% for average-risk and 70% for high-risk patients.[1]
However, prognosis remains poor for patients with recurrent
MB. Recently, four molecular subgroups have been described
(wingless/integrated [WNT], sonic hedgehog [SHH], Group 3,
and Group 4) that differ in their demographics, transcriptomes,
somatic genetic events and clinical outcomes.[2]
CNS malignancies can be associated with different neuroge-
netic syndromes, including tuberous sclerosis complex (TSC).
TSC is an autosomal dominant neurocutaneous disease affect-
ing about one in 6,000 newborns, and characterized by the pres-
ence of widespread hamartomas. CNS involvement results in a
high rate of epilepsy, mental retardation, and neuropsychiatric
disorders.[3] This disease has a variable expression ranging from
severe mental retardation, intractable seizures, and extensive or-
gan involvement to patients presenting few and asymptomatic
hamartomas, normal cognitive levels, and no seizures. Mam-
malian target of rapamycin (mTOR) overactivation is the key
finding in TSC.[4] Experimental findings suggest that inactiva-
tion of TSC genes can cooperate with SHH signaling to drive
tumor growth through mTOR-dependent translation machin-
ery.[5] Although patients with TSC are at increased risk of devel-
oping CNS malignancies,[6] an association with MB has never
been described.
RESULTS
Our patient was born at term after the first uneventful preg-
nancy to healthy unrelated parents. At 14 months of age, she
began to present focal seizures. Magnetic resonance imaging
(MRI) revealed the presence of several cortico-subcortical tu-
bers associated with small subependymal lesions, leading to a
definite diagnosis of TSC according to revised diagnostic cri-
teria.[7] Further investigation revealed the presence of a single
ash-leaf hypomelanotic macule and cardiac rhabdomyomas.
Additional Supporting Information may be found in the online ver-
sion of this article.
Abbreviations: CNS, central nervous system; EEG, electroen-
cephalogram; EGFL11, alias of EYS: eyes shut homolog;
GABRA5, gamma-aminobutyric acid (GABA) A receptor, alpha
5; Gd, gadolinium; H&E, haematoxilin and eosin; IMPG2, inter-
photoreceptor matrix proteoglycan 2; LC/A, large cell/anaplastic;
MAB21L2, mab-21-like 2; MB, medulloblastoma; MRI, magnetic
resonance imaging; mTOR, mammalian target of rapamycin;
mTORC, mTOR complex; NRL, neural retina leucine zipper;
RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma; SEGA,
subependymal giant cell astrocytoma; SHH, sonic hedgehog; TSC,
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Seizure control was obtained by carbamazepine. Normal
psychomotor development was observed thereafter. Molecu-
lar genetic analysis on peripheral blood cells, including next-
generation sequencing and multiplex ligation-dependent probe
amplification, revealed no mutations.
At the age of 5 years and 7 months, she presented with tor-
ticollis associated with headache, vomiting, and ataxia. MRI
showed a large rounded cerebellar lesion, arising from the ver-
mis and occupying the fourth ventricle with secondary hydro-
cephalus. A second mass was observed in the pituitary peduncle
(Fig. 1A).
After endoscopic third ventriculostomy, subtotal resection
was performed with residual disease on the floor of the fourth
ventricle. Cerebro-spinal fluid sampling confirmed dissemina-
tion of disease. A postoperative posterior fossa syndrome was
observed from which the patient had completely recovered at
40 days from surgery.
Histology documented a large cell/anaplastic (LC/A) MB
(Fig. 1B). Overexpression of NRL (neural retina leucine zipper),
NRP3,MAB21L2 (mab-21-like 2), IMPG2 (interphotoreceptor
matrix proteoglycan 2), EGFL11 (alias of EYS: eyes shut ho-
molog), and GABRA5 (gamma-aminobutyric acid [GABA] A
receptor, alpha 5) was suggestive of a molecular Group 3 MB
(Fig. 2A).MYC was not amplified but messenger RNA expres-
sion levels of both c-myc and n-myc were higher than in normal
cerebellar tissue (Fig. 2B).
Western blot analysis showed strong expression of mTOR
and its phosphorylated form (Fig. 2C). Nomutations were iden-
tified in theMB, thus excluding the presence of TSC1 andTSC2
somatic mutation in the tumor.
The patient was treated with a tailored chemotherapeutic
regime based on methotrexate, cyclophosphamide, and carbo-
platin plus vincristine. Complete remission of disease was ob-
tained and two courses of high-dose thiotepa with autologous
peripheral hemopoietic stem cell rescue were administered. Con-
sidering the pivotal role of mTOR in the pathogenesis of TSC-
associated tumors, off-label treatment with everolimus, a selec-
tive inhibitor of mTOR pathway, was started. Radiotherapy
was discussed but not performed and the patient is alive and in
complete remission of the disease at 17 months from diagnosis.
Antiepileptic treatment was gradually stopped without any elec-
troencephalogram (EEG) evidence of residual epileptic activity.
DISCUSSION
MB is the most common malignant brain tumor in children
and, despite recent treatment advances, approximately 40% of
children experience tumor recurrence and 30% will die of their
disease. Molecular profiling of MB has recently emerged as a
tool for risk stratification with molecular subgroup 3 having the
worst prognosis.[1] Group 3 tumors account for 28% of all MBs,
have a high incidence of LC/A histology and are very frequently
metastatic. LC/A MB are characterized by c-myc overexpres-
sion, which is highly associated with a worse clinical outcome.[1]
Our patient presented several poor prognosis indicators, includ-
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Fig. 1. (A) Axial CT scan (a); axial T2-weighted image (b); ADC
map (c); Gd-enhanced axial T1-weighted images (d and e); Sagit-
tal T1-weighted image (f). The midline mass is slightly hyperdense
to brain on CT scan (a). The lesion is slightly hyperintense on
T2-weighted images (b). Diffusion weighted imaging—ADC map
(c) showing areas of restricted diffusion due to the high cellular-
ity/high nucleus–cytoplasm ratio. Marked and inhomogeneous en-
hancement is seen following gadolinium administration (d). Axial
image shows thick neoplastic infiltration of the fourth ventricular
floor (arrow heads, b). The sagittal T1-weighted image (d) shows
that the hypointense lesion arises from the vermis and fills the fourth
ventricle. There is gross dilatation of the superior part of the fourth
ventricle and supratentorial hydrocephalus. Note a secondary lesion
at the level of the infundibulum (arrow; a, e, and d), and downward
tonsillar displacement (f). (B) Highly cellular neoplasia composed
of round small/medium-sized cells, with hyperchromatic nuclei and
scanty cytoplasm. Nuclear polymetrism and atypical mitoses are ev-
ident (H&E stain); diffuse pattern of synaptophysin positivity of
neoplastic cells; high proliferation rate (Ki67 IHC stain). Reticulin
stain revealed/showed a diffuse pattern of growth without pale area
formation or nodularity features.
ing LC/A histology, molecular subgroup 3, metastatic disease,
and residual disease after surgery.
Although MBs are more often sporadic, they can be found
in different syndromic conditions such as Gorlin syndrome, fa-
milial adenomatous polyposis, Fanconi anemia, RASopathies,
Rubinstein–Taybi syndrome, Mowat–Wilson syndrome, and
Turner syndrome.[8–12] The most frequent CNS tumors in TSC
Pediatr Blood Cancer DOI 10.1002/pbc
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Fig. 2. (A) MB molecular characterization and c-MYC expression—messenger RNA (mRNA) levels of the indicated genes in MB com-
pared to normal cerebellum (average, n = 8) as control (CTRLs). Genes are grouped and depicted in different colors, depending on the
molecular subgroup, which are identified as SHH,WNT,Group 3, andGroup 4. The values of relative quantification are expressed in linear
scale arbitrary units. (B) Histograms showing mRNA expression levels of c-MYC (left panel) and n-MYC (right panel) in MB compared
to normal cerebellum (average, n = 8) as CTRLs. (C) MB tissue samples were lysed in Ripa buffer and resolved by 8% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting anti-P-mTOR was performed to evaluate mTOR activation.
are subependymal giant cell astrocytomas (SEGA), CNS ma-
lignancies that are exceedingly rare and limited to glioblastoma
multiforme.[6,7] To our knowledge, this is the first report of MB
associated with TSC.
As regards any tumor predisposing condition, we speculate
that the genetic substrate of TSC might have played a role in
the onset of theMB in our patient. TSC commonly results from
mutations in the TSC1 or TSC2 genes encoding hamartin and
tuberin, respectively.[13] Ten to 25 percent of patients affected by
TSC have no mutation identifiable by available genetic testing,
and therefore in these cases a definite diagnosis is made using
clinical diagnostic criteria.[7]
Independent of mutational status, hamartin/tuberin dysfunc-
tion is a central event in TSC pathogenesis, leading to overacti-
vation of the mTOR pathway that is responsible for the forma-
tion of hamartomas and malignancies typical of TSC.[14–16]
Notably, TSC2mutation has also been reported in MB samples
and, more recently, TSC1mutation has been detected in Group
3 MB.[2,17] RAS/RAF-mediated m-TORC activation has also
been described in MB with resulting c-MYC translational regu-
lation conditioning cell growth and proliferation.[18,19]
Our patient showed normal expression of TSC1 and TSC2
both on blood samples and tumor tissue. However, mTOR was
activated as shown by its phosphorylated status, and c-MYCwas
overexpressed with no evidence of amplification.
We hypothesize a key role for TSC1/TSC2-independent acti-
vation of mTOR in the pathogenesis of both TSC and MB. Of
note, our patient showed a surprising sensitivity to chemother-
apy with complete remission of disease after only two treatment
courses without radiation therapy. Beginning treatment early
Pediatr Blood Cancer DOI 10.1002/pbc
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after surgery (15 days), when the blood–brain barrier had not
recovered, might have played a role in maximizing response to
treatment. Despite the well-documented role of radiation in the
treatment of MB, we decided to omit it considering the dramatic
response to chemotherapy and the risk of secondary malignan-
cies due to her cancer predisposition syndrome.
Based on the previous reports for SEGAs, our child re-
ceived a dose of 3 mg/m2 of everolimus (range 5–15 ng/ml),
and we speculate that this treatment might have contributed to
remission of disease. Moreover, although no specific effect on
epilepsy can be inferred as clinical seizures had not been ob-
served for a long time before tumor diagnosis, our patient had
a complete normalization of her EEG 6 months after treatment
initiation.[20]
In conclusion, patients affected by TSC should be considered
at risk for CNS malignancies, and the posterior fossa should be
considered in all neuroradiologic examinations. MB associated
with TSC may have a different behavior from comparable spo-
radic MB with a more favorable outcome. Indications for radi-
ation therapy should be considered on an individual basis, es-
pecially in the presence of a dramatic response to chemother-
apy. Considering the pivotal role of mTOR activation in TSC, it
should be tested in all associated malignancies to guide targeted
therapy.
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